Abstract 1544: Cell penetrating single domain antibody (sdAb) SBT-100 binds KRAS and inhibits growth of human cancers with KRAS activating mutations
Abstract Background: Despite nearly fourth years of research, scientists have failed to develop a clinically viable therapy against KRAS, one of the deadliest families of cancer-causing proteins. Mutations in KRAS are prevalent amongst the top three most deadly cancer types in the United States: pan...
Saved in:
Published in | Cancer research (Chicago, Ill.) Vol. 79; no. 13_Supplement; p. 1544 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
01.07.2019
|
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!